What This Asset
Is Worth — and Why.

The Valuation Framework

Professional domain appraisers evaluate assets on a standard set of criteria: extension quality, character count, category specificity, exact-match potential, search volume of component keywords, comparable sales, and the economic size of the target industry.

On each dimension, CrisprPharmaceuticals.com lands in the top tier:

• ✓.COM — the only extension that matters in institutional biotech
• ✓CRISPR — one of the most recognized scientific terms globally, Nobel-level recognition
• ✓Pharmaceuticals — the highest-authority word in drug development
• ✓Exact-match to a multi-billion-dollar, fast-growing industry
• ✓High organic search volume for component keywords
• ✓No existing trademark conflicts — clean for registration in pharma/biotech classes

The Branding Agency Comparison

A Fortune 500 or well-funded biotech hiring a top naming and branding agency — Landor, Interbrand, FutureBrand, Lexicon — for a full corporate naming project will invest between $250,000 and $1,000,000. That process takes 6–12 months and delivers a shortlist of candidates that then require trademark clearance, consumer testing, and legal review.

The result is rarely a name as immediately credible and category-aligned as CrisprPharmaceuticals.com. The domain short-circuits the entire process with an outcome that cannot be replicated by any agency engagement.

Domain Portfolio Context

For domain portfolio investors, CrisprPharmaceuticals.com represents an asymmetric opportunity. The gene editing sector is in a growth phase that parallels early-stage internet infrastructure — the category is real, the commercial applications are proving out, and the brand infrastructure (domains, trademarks) is being claimed now by well-funded companies. Domain prices in breakthrough sectors historically rise significantly as the sector matures.